Strategies for cancer stem cell elimination: Insights from mathematical modeling

Journal of Theoretical Biology

Volumn 298, Issue , 2012, Pages 32-41

  Vainstein, Vladimir ^a   Kirnasovsky, Oleg U ^a   Kogan, Yuri ^a   Agur, Zvia ^a  

^a Institute for Medical Biomathematics Isarel   (Israel)

Author keywords

Cancer therapy; Cell differentiation; Cellular automata

Indexed keywords

CANCER; CELLULAR AUTOMATON; DISEASE TREATMENT; GROWTH RATE; HYPOTHESIS TESTING; TUMOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CELL SUBPOPULATION; CELL TYPE; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; CONTROLLED STUDY; DYNAMICS; ENVIRONMENTAL FACTOR; FEEDBACK SYSTEM; HOMEOSTASIS; LIFESPAN; MALIGNANT TRANSFORMATION; MATHEMATICAL MODEL; NEGATIVE FEEDBACK; POPULATION SIZE; PRIORITY JOURNAL; QUORUM SENSING; REGULATORY MECHANISM;

CELL DIFFERENTIATION; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; STOCHASTIC PROCESSES;

EID: 84855818081     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.12.016     Document Type: Article

References (51)

1. Abbott L.H., Michor F. Mathematical models of targeted cancer therapy. Br. J. Cancer 2006, 95:1136-1141.
2. Adams J.M., Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 2008, 68(11):4018-4021.
3. Adamson P.C., Matthay K.K., O'Brien M., Reaman G.H., Sato J.K., Balis F.M. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch. NCI and Children's Oncology Group Study. Pediatr. Blood Cancer 2007, 49(5):661-665.
4. Agur Z., Daniel Y., Ginosar Y. The universal properties of stem cells as pinpointed by a simple discrete model. J. Math. Biol. 2002, 44:79-86.
5. Agur Z., Kogan Y., Levi L., Harrison H., Lamb R., Kirnasovsky O.U., Clarke R.B. Disruption of a Quorum sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. Biol. Direct 2010, 5.
6. Ashkenazi R., Jackson T.L., Dontu G., Wicha M.S. Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Rev. 2007, 3(2):176-182.
7. Bankhead A., Magnuson N.S., Heckendorn R.B. Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma in situ. J. Theor. Biol. 2007, 246:491-498.
8. Boman B.M., Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J. Clin. Oncol. 2008, 26(17):2828-2838.
9. Boman B.M., Wicha M.S., Fields J.Z., Runquist O.A. Symmetric Division of Cancer Stem Cells - a Key Mechanism in Tumor Growth that should be Targeted in Future Therapeutic Approaches. Clin. Pharmacol. Ther. 2007, 81(6):893-898.
10. Clarke R.B., Anderson E., Howell A., Potten C.S. Regulation of human breast epithelial stem cells. Cell Prolif. 2003, 36(Suppl 1):45-58.
11. Cortes-Dericks L., Carboni G.L., Schmid R.A., Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int. J. Oncol. 2010, 37(2):437-444.
12. Culine S., Kramar A., Droz J.P., Theodore C. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J. Urol. 1999, 161(1):173-175.
13. d'Onofrio A., Tomlinson I.P.M. A nonlinear mathematical model of cell turnover, differentiation and tumorigenesis in the intestinal crypt. J. Theor. Biol. 2007, 244:367-374.
14. Dingli D., Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells. 2006, 24(12):2603-2610.
15. Dingli D., Traulsen A., Michor F. (A)Symmetric stem cell replication and cancer. PLoS Comput. Biol. 2007, 3(3).
16. Enderling H., Anderson A.R., Chaplain M.A., Beheshti A., Hlatky L., Hahnfeldt P. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res. 2009, 69(22):8814-8821.
17. Enderling H., Hlatky L., Hahnfeldt P. Migration rules: tumours are conglomerates of self-metastases. Br. J. Cancer 2009, 100:1917-1925.
18. Enderling H., Hlatky L., Hahnfeldt P. Tumor morphological evolution: directed migration and gain and loss of the self-metastatic phenotype. Biol. Direct 2010, 5(23).
19. Flake A.W. The conceptual application of systems theory to stem cell biology: a matter of context. Blood Cells Mol. Dis. 2004, 32(1):58-64.
20. Ganguly R., Puri I.K. Mathematical model for the cancer stem cell hypothesis. Cell Prolif. 2006, 39(1):3-14.
21. Iida K., Kawai K., Hayashi H., Sekido N., Miyanaga N., Takeshima H., Akaza H. Cases of refractory testicular cancer treated with all trans-retinoic acid. Gan To Kagaku Ryoho 1999, 26(6):841-844.
22. Johnston M.D., Edwards C.M., Bodmer W.F., Maini P.K., Chapman S.J. Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc. Natl. Acad. Sci. USA 2007, 104:4008-4013.
23. Kakarala M., Wicha M.S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 2008, 26(17):2813-2820.
24. Kavalerchik E., Goff D., Jamieson C.H. Chronic myeloid leukemia stem cells. J. Clin. Oncol. 2008, 26(17):2911-2915.
25. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317(5836):337.
26. Kirnasovsky O.U., Kogan Y., Agur Z. Resilience in stem cell renewal: development of the Agur-Daniel-Ginossar model. Disc. Cont. Dyn. Syst. 2008, 10:129-148.
27. Kirnasovsky O.U., Kogan Y., Agur Z. Analysis of a mathematical model for the molecular mechanism of fate decision in mammary stem cells. Math. Mod. Nat. Phenom. 2008, 3:78-89.
28. Kirouac D.C., Madlambayan G.J., Yu M., Sykes E.A., Ito C., Zandstra P.W. Cell-cell interaction networks regulate blood stem and progenitor cell fate. Mol. Syst. Biol. 2009, 5:293.
29. le Viseur C., Hotfilder M., Bomken S., Wilson K., Rottgers S., Schrauder A., Rosemann A., Irving J., Stam R.W., Shultz L.D., Harbott J., Jurgens H., Schrappe M., Pieters R., Vormoor J. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008, 14(1):47-58.
30. Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr. Relat. Cancer 1999, 6:13-16.
31. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., Shaji R.V., Srivastava V.M., Srivastava A., Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107:2627-2632.
32. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27(7):1007-1013.
33. Michor F., Nowak M.A., Frank S.A., Iwasa Y. Stochastic elimination of cancer cells. Proc. R. Soc. London B 2003, 270:2017-2024.
34. Moreira J., Deutsch A. Cellular automaton models of tumor development: a critical review. Adv. Complex Syst. 2002, 5:247-267.
35. Pohl A., Lurje G., Kahn M., Lenz H.J. Stem cells in colon cancer. Clin. Colorectal Cancer 2008, 7(2):92-98.
36. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456(7222):593-598.
37. Rowe, J.M., Tallman, M.S., 2009. Therapy for acute myeloid leukemia. In: Hoffman, et al.(ed.), Hematology, New York.
38. Salmon S.E., Sartorelli A.C. Cancer chemotherapy. Basic and Clinical Pharmacology, International Edition 2001, 923-1044. Lange Medical Books/McGraw-Hill. B.G. Katzung (Ed.).
39. Sanchez-Garcia I., Vicente-Duenas C., Cobaleda C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice?. Bioessays 2007, 29(12):1269-1280.
40. Sell S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 2004, 51:1-28.
41. Sinicrope F.A., Hart J., Hsu H., Lemoine M., Michelassi F., Stephens L.C. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin. Cancer Res. 1999, 5:1793-1804.
42. Sottoriva A., Verhoeff J.J.C., Borovski T., McWeeney S.K., Naumov L., Medema J.P., Sloot P.M.A., Vermeulen L. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res. 2010, 70(1):46-56.
43. Spira A.I., Carducci M.A. Differentiation therapy. Curr. Opin. Pharmacol. 2003, 3(4):338-343.
44. Studer U.E., Jenzer S., Biedermann C., Chollet D., Kraft R., von Toggenburg H., Vonbank F. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur. Urol. 1995, 28(4):284-290.
45. Tomasson M.H. Cancer stem cells: a guide for skeptics. J. Cell Biochem. 2009, 106(5):745-749.
46. Tomlinson I.P.M., Bodmer W.F. Failure of programmed cell death and differentiation as causes of tumors: Some simple mathematical models. Proc. Natl. Acad. Sci. USA 1995, 92:11130-11134.
47. Trump D.L., Smith D.C., Stiff D., Adedoyin A., Day R., Bahnson R.R., Hofacker J., Branch R.A. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother. Pharmacol. 1997, 39(4):349-356.
48. Tu K.C., Long T., Svenningsen S.L., Wingreen N.S., Bassler B.L. Negative feedback loops involving small regulatory RNAs precisely control the Vibrio harveyi quorum-sensing response. Mol. Cell 2010, 37:567-579.
49. van Leeuwen I.M.M., Edwards C.M., Ilyas M., Byrne H.M. Towards a multiscale model of colorectal cancer. World J. Gastroenterol. 2007, 13(9):1399-1407.
50. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8(10):806-823.
51. Zhu X., Zhou X., Lewis M.T., Xia L., Wong S. Cancer stem cell, niche and EGFR decide tumor development and treatment response: a bio-computational simulation study. J. Theor. Biol. 2011, 269:138-149.